Thursday, July 11, 2024



Patient Care Data Drives Kite Pharma’s CAR T Cell Therapy Advancements, Emphasizing Real-World Evidence

Healthcare innovations continue to reshape patient care, with recent advancements coming from Kite Pharma, a subsidiary of Gilead Sciences. Early last month, the company...

Promising Results for HIV Prevention: Gilead’s Lenacapavir Achieves 100% Efficacy

HIV prevention in cisgender women shows promising interim results from Gilead Sciences' Phase III PURPOSE 1 trial, which evaluates the efficacy of the twice-yearly...

FDA Approves Biktarvy for Pregnant People with HIV: Key Study Insights

Gilead Sciences recently disclosed that the FDA has expanded the label for Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) to encompass its utilization in pregnant people living with...

Latest news